The Clinical Times
The Front Page of Medicine

Latest medical news · page 43

The latest headlines across every section, pulled from official and open-access sources.

ACC (Cardiology) · Jul 22, 2026

Does Influenza Vaccination Reduce AFib Risk?

Influenza vaccination was associated with lower risks of incident atrial fibrillation (AFib) and multiple cardiovascular outcomes, according to an observational cohort study published July 11 in EHJ. The findings support vaccination as a potential AFib prevention strategy and underscore the need for randomized trials focused on AFib-related outcomes.

ACC (Cardiology) · Jul 22, 2026

GBD 2023: High SBP, Diet and High LDL-C Top Drivers of US IHD Deaths

Nearly 90% of ischemic heart disease (IHD) deaths in 2023 in the U.S. were attributable to modifiable risk factors, led by high systolic blood pressure (SBP), dietary risks and high LDL-C, according to data from the Global Burden of Disease Study 2023 (GBD 2023), published July 15 in JAMA Cardiology.

FDA Drugs · Jul 22, 2026

Health Fraud Scams

Learn how to spot health fraud and avoid it.

NCQA · Jul 22, 2026

Public Comment Opens Soon: Proposed Retirement of Select HEDIS® Measures

NCQA is evolving HEDIS to better reflect where quality measurement is headed: toward a more focused and meaningful measure set that delivers clearer, more actionable signals and supports improvement in care, accountability and value across the healthcare system. Measure retirement is an important part of this ongoing curation work, helping ensure that HEDIS adapts to […] The post Public Comment Opens Soon: Proposed Retirement of Select HEDIS® Measures appeared first on NCQA .

ACC (Cardiology) · Jul 22, 2026

IL-6 as a Predictor of CV Risk Assessment: Role of Canakinumab and Ziltivekimab in Preventive Cardiology

The 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia identified low-density lipoprotein cholesterol (LDL-C) as the primary lipoprotein for therapeutic targeting.1 Similarly, lipoprotein(a) [Lp(a)] and high-sensitivity C-reactive protein (hs-CRP) also have long-standing independent associations with the development of atherosclerotic cardiovascular disease (ASCVD).

Fierce Biotech · Jul 22, 2026

NIH joins Trump’s $5B AI mission with biomedical research push

The U.S. Department of Health and Human Services announced new efforts Wednesday aligned with President Donald Trump’s artificial intelligence-driven Genesis Mission. The centerpiece of HHS’ participation is the NIH-led Bio Genesis Mission

MedCity News · Jul 22, 2026

Hidden in Plain Sight: The Cost Crisis in Women’s Healthcare

Women have to navigate the fragmented system with very little support, coordinating between providers and often interpreting conflicting guidance. The post Hidden in Plain Sight: The Cost Crisis in Women’s Healthcare appeared first on MedCity News .

PLOS Medicine · Jul 22, 2026

Whose fears count? Legitimacy, trust and viral outbreak responses after COVID-19

by Rebecca F. Grais COVID-19 transformed viral outbreak response from a predominantly public health challenge into a political and security concern. Recent responses to Ebola, mpox, and other emerging infections suggest that preparedness is increasingly shaped by whose fears are prioritized in decision-making. The challenge is ensuring that competing perceptions of risk are managed in ways that are perceived as legitimate, fair, and inclusive. In this Editorial, Rebecca Grais outlines how COVID-19 transformed viral outbreak responses from a predominantly public health challenge into a…

MedCity News · Jul 22, 2026

Better Prescribing, Not Less Prescribing, Is What Behavioral Health Needs

The policy conversation needs to shift from just deprescribing alone to building the clinical infrastructure that delivers consistent, high-quality behavioral health care. The post Better Prescribing, Not Less Prescribing, Is What Behavioral Health Needs appeared first on MedCity News .

FDA Enforcement · Jul 22, 2026

Drug recall: Clinere, Carbamide Peroxide

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%). — Bell Pharmaceuticals, Inc · Class II · Ongoing · 29, 474 units

← NewerOlder →

Back to the live front page